Effect of fluvastatin on low-density lipoprotein peak particle diameter

American Journal of Cardiology

Volumn 80, Issue 1, 1997, Pages 78-81

  Superko, H Robert ^a,b   Krauss, Ronald M ^a   DiRicco, Connie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cholesterol Genet Heart Dis Inst   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031195255     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00288-9     Document Type: Article

References (21)

1. 1. Superko, HR. Beyond LDL-C reduction. Circulation 1996;94:2351-2354.
2. 2. Pitt B, Mancini J, Ellis SG, Rosman HS, Park JS, McGovern ME, and PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I). J Am Coll Cardiol 1995;26:1133-1139.
3. 3. Jukema JW, Bruschke VG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, and The REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels (REGRESS). Circulation 1995;91:2528-2540.
4. 4. Shepherd J, Cobbe SM, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
5. 5. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-349.
6. 6. Stampfer MJ, Krauss RM, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low density lipoprotein panicle diameter, and risk of myocardial infarction. JAMA 1996;5:882-888.
7. 7. Gardner, CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996:276:875-881.
8. 8. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation 1997;95:69-75.
9. 9. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltavt DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993;42:1461-1467.
10. 10. Superko HR. Lipid disorders contributing to coronary heart disease - an update. Curr Probl Cardiol 1996;21:733-780.
11. 11. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit or therapy in the Stanford Coronary Risk Intervention project. Circulation 1996;94:2146-2153.
12. 12. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49.
13. 13. Mack W, Krauss RM, Hodis HN. Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS) Arterioscler Thromb Vasc Biol 1996;16:697-704.
14. 14. Dreon DM, Fernstrom H, Miller B, Krauss RM. Low density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J 1994;8:121-126.
15. 15. Myers GL, Cooper GR, Winn CL, Smith SJ. The Center for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 1989;9:105-135.
16. 16. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993;102:107-119.
17. 17. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. J Lab Clin Med 1989;114: 250-256.
18. 18. Viterbo CG, Krauss RM, Dobs AS. Low density lipoprotein (LDL) particle size changes with lovastatin treatment. Clin Res 1992;40:219A
19. 19. De Graaf J, Demacker PNM, Stalenhoef AFH. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia. Neth J Med 1993;43:254-261.
20. 20. Zhao SP, Hollaar L, van't Hooft FM, Smelt AHM, Leuven JAG, van der Laarse A. Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia. Clin Chim Acta 1991;203:109-118.
21. 21. Yuan J, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991;87: 147-157.